Forte Biosciences, Inc.
FBRX•NASDAQ•Healthcare•Biotechnology

About Forte Biosciences

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOPaul A. Wagner
Employees14
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.fortebiorx.com
Phone310 618 6994
Address
3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States

Corporate Identifiers

CIK0001419041
CUSIP34962G109
ISINUS34962G2084
EIN26-1243872
SIC2834

Leadership Team & Key Executives

Dr. Paul A. Wagner Ph.D.
Chief Executive Officer, President and Chairman
Antony A. Riley CPA
Chief Financial Officer
Dr. Barbara K. Finck M.D.
Chief Medical Clinician and Director
Christopher Roenfeldt
Chief Operating Officer